Sandoz enters US generic injectables market
Executive Summary
Sandoz' acquisition of Canadian generic manufacturer Sabex will give the firm entry into the U.S. sterile injectable market, the company said June 7. The injectable medicines Infufer (iron dextran) and hydromorphone are Sabex' leading U.S. products. The company makes a total of 89 Canadian generic molecules in its FDA-approved facilities. The deal also allows Sandoz to bring its solid oral generics to the Canadian market. The $565 mil. cash transaction is expected to close in July. Sandoz plans to retain the entire Sabex management team...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.